King Pharmaceuticals to Present at Wachovia Capital Markets Conference
June 18, 2009
BRISTOL, TENNESSEE, June 18, 2009 – King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to provide a live webcast of its presentation scheduled for Wednesday, June 24, 2009, at 11:15 a.m., ET, at the Wachovia 2009 Mid-Year Equity Conference at The InterContinental Hotel in Boston, Massachusetts. The presentation may include a discussion of the Company’s marketed products, pipeline, strategy for growth, financial results and expectations, and other matters relating to its business. Interested persons may access the live webcast via the internet on the King Pharmaceuticals website at http://www.kingpharm.com/webcasts/. A replay of the webcast may be accessed at this same link for a period of not less than 14 days after the live event.
About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company’s focus in specialty-driven markets, particularly neuroscience and hospital. King is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.
Forward-looking Statements
This release contains forward-looking statements which reflect management’s current views of future events and operations, including, but not limited to, statements pertaining to the anticipated webcast of the Company’s presentation on June 24, 2009. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. An important factor which may cause results to differ is whether King is able to webcast the presentation on June 24, 2009 as currently planned. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
# # #
Contacts:
Jack Howarth, Vice President, Investor Relations
908-429-8350
Executive Offices:
King Pharmaceuticals
501 Fifth Street
Bristol, Tennessee 37620
